Get started

Benitec

BNTC Gene Therapy Penny Stock at All Time LowBNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics. BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it. On 2/17/2022 P. Trucchio from HC Wainwright brokerage Initiated Coverage for BNTC with a Buy rating and a price target of $10.00. The price of the stock can easily double in my opinion.
NASDAQ:BNTCLong
by TopgOptions
1
BNTC Gene Therapy Penny StockBTC Benitec Biopharma is sitting now at a key support from which we can expect a bounce. We know that earlier this year they had a 7.5mil offering price to the public of $4.25 per share and that Morgan Stanley has a 5.2% stake in the genetic drug company. Benitec's "proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Market Cap 22.472Mil My price targets are 4.70 and 5.70 usd.
NASDAQ:BNTCLong
by TopgOptions
BNTC Benitech Biopharma we bought the dipMorgan Stanley disclosed in an SEC filing that it had increased its stake in the company by around 5.2%! Don`t worry, it has still upside potential, despite the 130% increase in the Pre-Market. Market Cap of only 15.37M This is a 5X stock, Not trading advice as you know! :) This was a private call from my trading group and one of my top picks for March. You can check the transcripts here: www.patreon.com If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:BNTCLong
by TopgOptions
16
Benitec Biopharma Inc. BNTC can explode anytime nowBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. (Source: Yahoo Finance) On April 15, 2020, the Company completed the re-domiciliation of the Company from Australia to the United States. As a result, the Company is now incorporated in the United States and its common stock is listed on Nasdaq. (Source: prnewswire.com) Market Cap 17.093M Please leave me a message if you want to test the buy and sell indicators that i am using.
NASDAQ:BNTCLong
by BuySellMarketMaker
2